Roche bullish on its diagnostics biz

The heads of Roche's ($RHHBY) diagnostics arm aren't worried about CMS reimbursement reductions, saying they are being offset by higher testing volumes. Most Big Pharma companies view diagnostics through the realm of companion diagnostics, but Roche has made the business one of its core competencies. (Just in case, don't expect the division to be sold off as part of the industry's continuing trend toward the streamlining of companies' business units.) Story

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.